Autopsy report · NCT05701189

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

“Study will not be proceeding due to continued difficulties with participant enrollment at a single site.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Chafic Karam

Sponsor type

University, hospital or other

Conditions

Guillain-Barre Syndrome

Interventions

Efgartigimod Alfa-Fcab; Intravenous Immunoglobulin (IVIg)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Keto-diet for Intubated Critical Care COVID-19
  “Study did not begin enrollment, multiple competing studies at same institution” (71% match in meaning)
• Methylene Blue in Sepsis: A Randomized Controlled Trial
  “primary site withdrew due to competing study: never enrolled any subjects.” (70% match in meaning)
• Vaginal Estradiol Use in Pessary Care
  “There is a lack of potential study participants at our study site that would meet inclusion criteria, therefore, the study is not feasible and is being terminated.” (70% match in meaning)
• A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
  “Due to a strategic decision by the company, the study will not proceed, and no subjects have been enrolled to date.” (70% match in meaning)
• OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
  “Study will be closed due to zero enrollment in over 2 years.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.